

XVIVO Perfusion – Consensus estimates Q3 2025

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q3 2025E
Net sales	185
Organic growth in local currency (%)	-0.30
Gross profit	138
EBITDA	30.4
EBIT	12.6
Net profit	9.56
Earnings per share (SEK)	0.31

XVIVO Perfusion's Q3 report will be released on Thursday 23 October at 07.30 CEST.